Presentation from OIS@ASCRS 2016 Paul McLean, CEO Video Presentation: https://www.youtube.com/watch?v=br9TMNFYFYk&index=21&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw

1. HARMONI® Modular IOL System
Paul McLean
President and CEO
5 May 2016

2. 2
HARMONI Modular IOL Design

3. 3
HARMONI Development Milestones
Technology
development
FIH Trial
1 Year Data
CE Mark
3 new trials
#1 Innovation
• Stable
• Replaceable
• Versatile
• Easy
• Multicenter
• Randomized
• Controlled
Confirmed:
• Stable
• Replaceable
• Versatile
• Easy
Trial execution
• 100’s of patients
• IDE building blocks
• Results Q4 2016
• Consistent results
2012
2013
2014
2015
2016

4. 0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
GLP Study
Alcon SA60 HARMONI
p=.003
3.00
3.50
4.00
4.50
5.00
5.50
6.00
Day 1 Month 1 Month 3 Month 6 Month 12
Outstanding Results
Visual Acuity
Average Days
Implanted
Pre-op
Avg. Error
(diopters)
Post-op
Avg. Error
(6 month)
94 -0.90 -0.02
ACD Stability
Optic Replacement
-0.3
-0.2
-0.1
0
0.1
0.2
BCVAlogMAR
Control HARMONI
PCO Development (Pre-clinical)
The HARMONI modular IOL is an investigational device and is not approved for use in the United States
PCOScore

5. ClarVista Highlights
5
 IOL performance you can count on, versatility and control you crave
 Solid foundation, versatile control
– Optimized patient outcomes
– Enhanced stability
 Technology for a lifetime
– Safe & easy IOL replacement and upgrades
– Intelligent design choices to decrease PCO
– One platform, all patients
 Platform technology - outstanding potential to go well beyond refractive correction
The HARMONI modular IOL is an investigational device and is not approved for use in the United States

6. HARMONI® Modular IOL System
For more information about the HARMONI Modular IOL please contact:
Paul McLean
pmclean@clarvistamedical.com
www.clarvistamedical.com
Twitter: @ClarVista_Med